Ang Lin, Song Eunhye, Hu Xiao-Yang, Lee Hye Won, Chen Yaolong, Lee Myeong Soo
KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea.
Global Cooperation Center, Korea Institute of Oriental Medicine, Daejeon, South Korea.
Front Pharmacol. 2022 Jun 20;13:906764. doi: 10.3389/fphar.2022.906764. eCollection 2022.
Integrative herbal medicine has been reported to have beneficial effects in the treatment of coronavirus disease 2019 (COVID-19). To compile up-to-date evidence of the benefits and risks of herbal medicine for the treatment of COVID-19 symptoms. Eleven databases, including PubMed, Cochrane Register of Controlled Trials (CENTRAL), Embase, Allied and Complementary Medicine Database (AMED), Chinese National Knowledge Infrastructure Database (CNKI), Wanfang Database, and Chinese Science and Technique Journals Database (VIP), Research Information Service System (RISS), Korean Medical database (KMBase), Korean Association of Medical Journal database (KoreaMed), and OASIS database, were searched from 15 June, 2020, until 28 March 2022. Randomized controlled trials (RCTs), published in any language, reporting the efficacy and safety outcomes of herbal medicine in patients of all ages with a PCR-confirmed diagnosis of COVID-19 were included in this analysis. Data extraction and quality assessments were performed independently. Random-effects meta-analyses showed evidence of favorable effects of treatment with herbal medicine when added to standard treatment, versus standard treatment alone, on the total effective rate ( = 0.0001), time to remission from fever ( < 0.00001), rate of remission from coughing ( < 0.0001), fatigue ( = 0.02), sputum production ( = 0.004), improvement of manifestations observed on chest computed tomography scans ( < 0.00001), incidence of progression to severe COVID-19 ( = 0.003), all-cause mortality ( = 0.003), time to a negative COVID-19 coronavirus test ( < 0.0001), and duration of hospital stay ( = 0.0003). There was no evidence of a difference between herbal medicine added to standard treatment, versus standard treatment alone, on the rate of remission from symptoms such as a fever, sore throat, nasal congestion and discharge, diarrhea, dry throat, chills, and the rate of conversion to a negative COVID-19 coronavirus test. Meta-analysis showed no evidence of a significant difference in adverse events between the two groups. There was an unclear risk of bias across the RCTs included in this analysis, indicating that most studies had methodological limitations. Current evidence suggests that herbal medicine added to standard treatment has potential benefits in the treatment of COVID-19 symptoms but the certainty of evidence was low.
据报道，中西医结合疗法在治疗2019冠状病毒病（COVID-19）方面具有有益效果。为了汇总有关草药治疗COVID-19症状的益处和风险的最新证据。检索了11个数据库，包括PubMed、Cochrane对照试验注册库（CENTRAL）、Embase、联合与补充医学数据库（AMED）、中国国家知识基础设施数据库（CNKI）、万方数据库、中国科技期刊数据库（VIP）、研究信息服务系统（RISS）、韩国医学数据库（KMBase）、韩国医学期刊协会数据库（KoreaMed）和绿洲数据库，检索时间为2020年6月15日至2022年3月28日。纳入本分析的是所有语言发表的随机对照试验（RCT），报告了经PCR确诊为COVID-19的各年龄段患者使用草药的疗效和安全性结果。数据提取和质量评估独立进行。随机效应荟萃分析显示，与单纯标准治疗相比，在标准治疗基础上加用草药治疗在总有效率（ = 0.0001）、退热时间（ < 0.00001）、咳嗽缓解率（ < 0.0001）、疲劳（ = 0.02）、痰液产生（ = 0.004）、胸部计算机断层扫描观察到的表现改善（ < 0.00001）、进展为重症COVID-19的发生率（ = 0.003）、全因死亡率（ = 0.003）、COVID-19冠状病毒检测转阴时间（ < 0.0001）和住院时间（ = 0.0003）方面有有利效果的证据。在标准治疗基础上加用草药治疗与单纯标准治疗相比，在发热、咽痛、鼻塞流涕、腹泻、咽干、寒战等症状的缓解率以及COVID-19冠状病毒检测转阴率方面，没有证据表明存在差异。荟萃分析显示两组在不良事件方面没有显著差异的证据。本分析纳入的RCT存在不明确的偏倚风险，表明大多数研究存在方法学局限性。目前的证据表明，在标准治疗基础上加用草药在治疗COVID-19症状方面有潜在益处，但证据的确定性较低。
